Cocrystal Pharma, Inc. — Director's Dealing 2015

Mar 5, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2015-03-03

Reporting Person: HSIAO JANE PH D (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-03-03	Common Stock	M	5496654	—	Acquired	5496654	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-03-03	Series B Convertible Preferred Stock	$	M	53626802	Disposed		Common Stock ()	Indirect

Footnotes

F1: Each share of Series B Convertible Preferred Stock held by the reporting person was automatically convertible for no additional consideration into 205.08308640 shares of the issuer's common stock at such time as the issuer obtained sufficient authorized capital. The issuer filed a charter amendment increasing its authorized common stock with the Secretary of State of Delaware on March 3, 2015, which caused the automatic conversion of the Series B Convertible Preferred Stock into common stock. The Series B Convertible Preferred Stock had no expiration date.

F2: The securities are owned directly by Hsu Gamma Investment, L.P., of which the reporting person is the general partner. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.